NASDAQ:ICAD - iCAD Stock Price, Price Target & More

$3.50 +0.11 (+3.24 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$3.39
Today's Range$3.38 - $3.51
52-Week Range$2.93 - $6.07
Volume17,306 shs
Average Volume34,149 shs
Market Capitalization$56.29 million
P/E Ratio-5.62
Dividend YieldN/A
Beta1.44

About iCAD (NASDAQ:ICAD)

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200

Debt

Debt-to-Equity Ratio0.36%
Current Ratio1.76%
Quick Ratio1.58%

Price-To-Earnings

Trailing P/E Ratio-5.62
Forward P/E Ratio-8.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$28.10 million
Price / Sales2.07
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book4.07

Profitability

EPS (Most Recent Fiscal Year)($0.61)
Net Income$-14,250,000.00
Net Margins-50.73%
Return on Equity-48.67%
Return on Assets-28.20%

Miscellaneous

Employees119
Outstanding Shares16,600,000

How to Become a New Pot Stock Millionaire

iCAD (NASDAQ:ICAD) Frequently Asked Questions

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How were iCAD's earnings last quarter?

iCAD Inc. (NASDAQ:ICAD) posted its quarterly earnings results on Thursday, March, 22nd. The technology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14). The technology company had revenue of $7.90 million for the quarter, compared to analyst estimates of $7.43 million. iCAD had a negative net margin of 50.73% and a negative return on equity of 48.67%. View iCAD's Earnings History.

When is iCAD's next earnings date?

iCAD is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for iCAD.

What price target have analysts set for ICAD?

1 analysts have issued 12-month target prices for iCAD's stock. Their predictions range from $11.00 to $11.00. On average, they expect iCAD's stock price to reach $11.00 in the next year. View Analyst Ratings for iCAD.

Who are some of iCAD's key competitors?

Who are iCAD's key executives?

iCAD's management team includes the folowing people:
  • Mr. Kenneth M. Ferry, CEO & Director (Age 64)
  • Mr. Richard C. Christopher, Exec. VP, CFO, Treasurer & Sec. (Age 48)
  • Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 50)
  • Mr. R. Scott Areglado, VP & Corp. Controller
  • Ms. Annette L. Heroux, VP of Admin. (Age 61)

Has iCAD been receiving favorable news coverage?

News articles about ICAD stock have trended somewhat positive on Monday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. iCAD earned a media sentiment score of 0.12 on Accern's scale. They also gave news headlines about the technology company an impact score of 45.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $3.50.

How big of a company is iCAD?

iCAD has a market capitalization of $56.29 million and generates $28.10 million in revenue each year. The technology company earns $-14,250,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. iCAD employs 119 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]


MarketBeat Community Rating for iCAD (ICAD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

iCAD (NASDAQ:ICAD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for iCAD in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 214.29%. The high price target for ICAD is $11.00 and the low price target for ICAD is $11.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$11.00$11.00
Price Target Upside: 214.29% upside179.19% upside179.19% upside179.19% upside

iCAD (NASDAQ:ICAD) Consensus Price Target History

Price Target History for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ:ICAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2017LaidlawReiterated RatingBuy$11.00MediumView Rating Details
(Data available from 4/23/2016 forward)

Earnings

iCAD (NASDAQ:ICAD) Earnings History and Estimates Chart

Earnings by Quarter for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ:ICAD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.06)($0.06)($0.06)

iCAD (NASDAQ ICAD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018        
3/22/2018Q4 2017($0.14)($0.14)$7.43 million$7.90 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.14)($0.13)$7.43 million$7.00 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.19)($0.1610)$6.41 million$6.41 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.18)$6.40 million$6.79 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.17)($0.20)$6.60 million$6.93 millionViewListenView Earnings Details
11/2/2016Q3 2016($0.14)($0.16)$7.44 million$6.00 millionViewN/AView Earnings Details
7/27/2016Q2($0.14)($0.09)$6.99 million$7.37 millionViewListenView Earnings Details
5/3/2016Q1($0.14)($0.17)$7.27 million$6.04 millionViewN/AView Earnings Details
3/1/2016Q4($0.17)($0.14)$7.77 million$7.61 millionViewN/AView Earnings Details
10/29/2015Q315($0.07)($0.03)$8.09 million$9.58 millionViewListenView Earnings Details
4/30/2015Q1 2015($0.01)$0.02$12.96 million$13.22 millionViewN/AView Earnings Details
2/24/2015Q414$0.04$0.01$13.30 million$13.20 millionViewN/AView Earnings Details
10/28/2014Q3 2014$0.04$11.56 million$12.57 millionViewN/AView Earnings Details
7/30/2014Q2 2014($0.02)($0.04)$9.02 million$9.67 millionViewN/AView Earnings Details
5/6/2014Q1($0.15)($0.12)$7.95 million$8.50 millionViewListenView Earnings Details
2/19/2014Q4($0.17)($0.41)$8.25 million$9.14 millionViewListenView Earnings Details
10/29/2013Q313($0.20)($0.11)$8.07 million$8.30 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.25)($0.12)$7.56 million$7.71 millionViewListenView Earnings Details
4/29/2013Q1 2013($0.14)($0.11)$7.20 million$7.93 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.15)$6.61 million$7.82 millionViewListenView Earnings Details
10/30/2012Q3 2012($0.20)($0.15)ViewN/AView Earnings Details
8/1/2012Q2 2012($0.25)($0.26)ViewN/AView Earnings Details
5/7/2012Q1 2012($0.30)($0.26)ViewN/AView Earnings Details
2/27/2012Q4 2011($0.25)($0.21)ViewN/AView Earnings Details
10/26/2011Q3 2011($0.35)($0.14)ViewN/AView Earnings Details
7/27/2011Q2 2011($0.35)($0.35)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.30)($0.32)ViewN/AView Earnings Details
3/23/2011Q4 2010($0.10)($0.07)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.05)($0.15)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.08)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.05)($0.15)ViewN/AView Earnings Details
2/22/2010Q4 2009$0.05$0.05ViewN/AView Earnings Details
10/28/2009Q3 2009($0.05)$0.01ViewN/AView Earnings Details
7/29/2009Q2 2009($0.05)($0.16)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.15)($0.11)ViewN/AView Earnings Details
2/25/2009Q4 2008$0.05$0.04ViewN/AView Earnings Details
10/29/2008Q3 2008$0.15$0.23ViewN/AView Earnings Details
7/31/2008Q2 2008$0.15$0.27ViewN/AView Earnings Details
5/7/2008Q1 2008($0.05)($0.06)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

iCAD (NASDAQ:ICAD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

iCAD (NASDAQ ICAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 20.98%
Insider Trading History for iCAD (NASDAQ:ICAD)
Institutional Ownership by Quarter for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ ICAD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2017Dr Lawrence HowardDirectorBuy10,000$3.33$33,300.00488,022View SEC Filing  
11/14/2016Kenneth M FerryCEOBuy10,000$3.50$35,000.00334,136View SEC Filing  
3/4/2016Kenneth M FerryCEOBuy25,000$4.45$111,250.00249,136View SEC Filing  
3/4/2016Kevin C BurnsCFOBuy10,000$4.44$44,400.00183,734View SEC Filing  
3/19/2015Kenneth M FerryCEOSell100,000$10.00$1,000,000.00View SEC Filing  
3/12/2015Somu SubramaniamDirectorSell50,762$9.23$468,533.26View SEC Filing  
2/10/2015Stacey M StevensSVPSell27,298$10.00$272,980.00View SEC Filing  
12/3/2014Stacey M StevensSVPSell2,502$10.00$25,020.00View SEC Filing  
12/2/2014Stacey M StevensSVPSell503$10.01$5,035.03View SEC Filing  
12/1/2014Stacey M StevensSVPSell299$10.00$2,990.00View SEC Filing  
11/11/2014Kenneth M FerryCEOSell18,318$11.09$203,146.62View SEC Filing  
11/3/2014Stacey M StevensVPSell10,000$11.31$113,100.00View SEC Filing  
10/1/2014Stacey M StevensVPSell13,333$10.00$133,330.00View SEC Filing  
9/3/2014Stacey M StevensVPSell10,000$10.94$109,400.00View SEC Filing  
8/27/2014Kevin C BurnsCFOSell36,439$10.44$380,423.16View SEC Filing  
8/25/2014Kenneth M FerryCEOSell40,000$10.71$428,400.00View SEC Filing  
8/20/2014Stacey M StevensVPSell5,000$10.57$52,850.00View SEC Filing  
8/19/2014Kenneth M FerryCEOSell20,000$10.06$201,200.00View SEC Filing  
8/26/2013Kenneth M FerryCEOBuy5,000$5.55$27,750.00View SEC Filing  
5/3/2013Kevin C BurnsCFOBuy2,900$5.19$15,051.00View SEC Filing  
8/24/2012Kevin C BurnsCFOBuy15,000$2.08$31,200.00View SEC Filing  
8/17/2012Kevin C BurnsCFOBuy28,939$2.90$83,923.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

iCAD (NASDAQ ICAD) News Headlines

Source:
DateHeadline
Java Blues by ICAD to Make Global Debut at The Superdesign Show MilanJava Blues by ICAD to Make Global Debut at The Superdesign Show Milan
finance.yahoo.com - April 23 at 8:11 AM
iCAD Announces Presentation of Positive Clinical Data on Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers at ESTRO 37iCAD Announces Presentation of Positive Clinical Data on Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers at ESTRO 37
finance.yahoo.com - April 19 at 8:11 AM
Laidlaw Reaffirms Buy Rating for iCAD (ICAD)Laidlaw Reaffirms Buy Rating for iCAD (ICAD)
www.americanbankingnews.com - April 16 at 12:37 PM
Active-Investors: Free Post Earnings Research Report: Nutanixs Revenues Surged 44%; Net Loss NarrowedActive-Investors: Free Post Earnings Research Report: Nutanix's Revenues Surged 44%; Net Loss Narrowed
www.finanznachrichten.de - April 12 at 8:25 AM
iCAD (ICAD) Upgraded to Sell by ValuEngineiCAD (ICAD) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 8 at 12:22 PM
Zacks Investment Research Weighs in on iCAD Inc.s Q1 2018 Earnings (ICAD)Zacks Investment Research Weighs in on iCAD Inc.'s Q1 2018 Earnings (ICAD)
www.americanbankingnews.com - April 5 at 7:38 AM
iCAD Inc. (ICAD) to Post FY2020 Earnings of $0.04 Per Share, Zacks Investment Research ForecastsiCAD Inc. (ICAD) to Post FY2020 Earnings of $0.04 Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - April 4 at 8:10 AM
BRIEF-Icad Q4 Gaap Loss Per Share $0.26BRIEF-Icad Q4 Gaap Loss Per Share $0.26
www.reuters.com - March 24 at 5:19 PM
iCAD reports stronger Q4 resultsiCAD reports stronger Q4 results
seekingalpha.com - March 23 at 5:48 PM
iCAD (ICAD) Releases Quarterly  Earnings Results, Meets EstimatesiCAD (ICAD) Releases Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - March 23 at 8:14 AM
Edited Transcript of ICAD earnings conference call or presentation 22-Mar-18 8:30pm GMTEdited Transcript of ICAD earnings conference call or presentation 22-Mar-18 8:30pm GMT
finance.yahoo.com - March 23 at 8:14 AM
iCAD Reports Fourth Quarter and Full-Year 2017 Financial ResultsiCAD Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 22 at 5:41 PM
iCAD (ICAD) Set to Announce Quarterly Earnings on ThursdayiCAD (ICAD) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 19 at 8:38 AM
iCAD to Report Fourth Quarter and Fiscal 2017 Financial Results on Thursday, March 22, 2018iCAD to Report Fourth Quarter and Fiscal 2017 Financial Results on Thursday, March 22, 2018
finance.yahoo.com - March 16 at 8:13 AM
iCAD (ICAD) Stock Rating Lowered by ValuEngineiCAD (ICAD) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 13 at 10:19 PM
Form 4 ICAD INC For: Feb 14 Filed by: Ecock Anthony FForm 4 ICAD INC For: Feb 14 Filed by: Ecock Anthony F
www.streetinsider.com - February 16 at 5:21 PM
iCAD Named a Top Artificial Intelligence Medical Imaging Solution Provider by Healthcare Tech OutlookiCAD Named a Top Artificial Intelligence Medical Imaging Solution Provider by Healthcare Tech Outlook
finance.yahoo.com - February 8 at 3:39 PM
BRIEF-iCAD Expects To Reduce About 18 Pct Of Workforce Across Skin Subscription BusinessBRIEF-iCAD Expects To Reduce About 18 Pct Of Workforce Across Skin Subscription Business
www.reuters.com - January 5 at 3:46 PM
iCAD (ICAD) Upgraded at ValuEngineiCAD (ICAD) Upgraded at ValuEngine
www.americanbankingnews.com - January 4 at 10:32 PM
iCAD (ICAD) Rating Lowered to Strong Sell at ValuEngineiCAD (ICAD) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM
ICAD: Study Shows IORT Superior To EBRT in Quality of Life, CostICAD: Study Shows IORT Superior To EBRT in Quality of Life, Cost
finance.yahoo.com - December 15 at 11:47 AM
Two Centers from The US Oncology Network Adopt iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin CancerTwo Centers from The US Oncology Network Adopt iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin Cancer
finance.yahoo.com - December 12 at 11:56 AM
iCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer TreatmentiCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer Treatment
finance.yahoo.com - December 7 at 11:47 AM
iCAD’s PowerLook® Tomo Detection Experiences Growing AdoptioniCAD’s PowerLook® Tomo Detection Experiences Growing Adoption
finance.yahoo.com - November 27 at 5:25 PM
Are iCAD Inc’s (ICAD) Interest Costs Too High?Are iCAD Inc’s (ICAD) Interest Costs Too High?
finance.yahoo.com - November 22 at 12:54 AM
ICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To AccelerateICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To Accelerate
finance.yahoo.com - November 13 at 7:45 PM
Edited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 11 at 10:46 AM
iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”
finance.yahoo.com - November 11 at 10:46 AM
icad inc. (ICAD) Issues  Earnings Resultsicad inc. (ICAD) Issues Earnings Results
www.americanbankingnews.com - November 9 at 7:48 PM
Icad reports 3Q lossIcad reports 3Q loss
www.cnbc.com - November 9 at 2:35 AM
Imaging For Women Now Offering ICADs PowerLook® Tomo Detection For Digital Breast TomosynthesisImaging For Women Now Offering ICAD's PowerLook® Tomo Detection For Digital Breast Tomosynthesis
www.thestreet.com - November 8 at 4:32 PM
iCAD, Inc. to Host Earnings CalliCAD, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 4:32 PM
iCAD Reports Third Quarter 2017 Financial ResultsiCAD Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 4:32 PM
Imaging for Women Now Offering iCAD’s PowerLook® Tomo Detection for Digital Breast TomosynthesisImaging for Women Now Offering iCAD’s PowerLook® Tomo Detection for Digital Breast Tomosynthesis
finance.yahoo.com - November 8 at 10:05 AM
The global brachytherapy market is expected to reach USD 486.9 million by 2025The global brachytherapy market is expected to reach USD 486.9 million by 2025
finance.yahoo.com - November 3 at 8:26 AM
icad inc. (ICAD) Scheduled to Post Earnings on Wednesdayicad inc. (ICAD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 2 at 9:53 AM
iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8
finance.yahoo.com - November 2 at 1:57 AM
iCAD’s PowerLook Tomo Detection for Digital Breast Tomosynthesis Named 2017 Product of the Year by New Hampshire High Technology CounciliCAD’s PowerLook Tomo Detection for Digital Breast Tomosynthesis Named 2017 Product of the Year by New Hampshire High Technology Council
finance.yahoo.com - October 26 at 12:40 PM
iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017
finance.yahoo.com - September 25 at 9:54 AM
iCAD to Present at the Cantor Fitzgerald Global Healthcare ConferenceiCAD to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 4:05 PM
Tech PR Agency ARPR Adds Two Marquee Health IT Brands to Its Portfolio; Erin Bocherer Hired as First Practice Group DirectorTech PR Agency ARPR Adds Two Marquee Health IT Brands to Its Portfolio; Erin Bocherer Hired as First Practice Group Director
www.marketwatch.com - September 14 at 11:31 PM
ETFs with exposure to iCAD, Inc. : September 6, 2017ETFs with exposure to iCAD, Inc. : September 6, 2017
finance.yahoo.com - September 6 at 6:15 AM
iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017
finance.yahoo.com - August 31 at 7:43 PM
BRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDABRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDA
www.reuters.com - August 31 at 6:00 AM
iCAD Announces Approval of Xoft® Axxent® Balloon Applicators by China Food & Drug Administration for Treatment of Early-Stage Breast CanceriCAD Announces Approval of Xoft® Axxent® Balloon Applicators by China Food & Drug Administration for Treatment of Early-Stage Breast Cancer
finance.yahoo.com - August 31 at 6:00 AM
icad inc. (ICAD) Director Acquires $33,300.00 in Stockicad inc. (ICAD) Director Acquires $33,300.00 in Stock
www.americanbankingnews.com - August 24 at 4:30 PM
icad inc. (ICAD) Expected to Earn FY2019 Earnings of $0.03 Per Shareicad inc. (ICAD) Expected to Earn FY2019 Earnings of $0.03 Per Share
www.americanbankingnews.com - August 18 at 2:08 PM
ICAD: A Look Behind Q2 Numbers. U.S. Tomo Launch EncouragingICAD: A Look Behind Q2 Numbers. U.S. Tomo Launch Encouraging
finance.yahoo.com - August 18 at 5:09 AM
Edited Transcript of ICAD earnings conference call or presentation 8-Aug-17 8:30pm GMTEdited Transcript of ICAD earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:29 AM
icad inc. (NASDAQ:ICAD) Issues Quarterly  Earnings Resultsicad inc. (NASDAQ:ICAD) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 9:30 PM

SEC Filings

iCAD (NASDAQ:ICAD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

iCAD (NASDAQ:ICAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

iCAD (NASDAQ ICAD) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.